ABBVIE INC.
ABBV
294.45−0.53 (−0.18%)Nov 12, 7:00 PM ET
Key stats
- Open
- 299.30
- Day high
- 300.42
- Day low
- 294.07
- Previous close
- 294.98
- Volume
- 4.83M
- VWAP
- 295.32
- 52-week high
- 302.93
- 52-week low
- 190.75
- Market cap
- 521.41B
- Shares out
- 1.77B
- Employees
- 57,000
- Listed
- 2012
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
PHARMACEUTICAL PREPARATIONS · NORTH CHICAGO, IL · abbvie.com
Options · expiring Nov 13
Nov 12, 4:00 PM ET- Call open interest
- 4.7K
- Put open interest
- 3.4K
- Put/call
- 0.73
- At-the-money IV
- 27.4%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 290 call | 6.07 | Nov 12, 3:08 PM | 908 | 1.1K | — |
| 270 put | 0.01 | Nov 12, 3:21 PM | 331 | 692 | 73.1% |
| 280 call | 15.66 | Nov 12, 2:10 PM | 326 | 350 | — |
| 272.50 put | 0.01 | Nov 12, 10:53 AM | 323 | 327 | 66.3% |
| 305 call | 0.03 | Nov 12, 3:55 PM | 218 | 461 | 36.1% |
| 297.50 call | 0.75 | Nov 12, 3:59 PM | 161 | 304 | 20.6% |
Quarterly results
Massive · Nov 3, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $17.40B | $16.99B | $15.00B | $16.62B |
| Gross profit | $13.12B | $12.70B | $10.78B | $12.07B |
| Operating income | $6.27B | $6.43B | $3.99B | $4.33B |
| Net income | $4.22B | $3.61B | $695.00M | $1.81B |
| Diluted EPS | 2.37 | 2.03 | 0.39 | 1.02 |
| Operating cash flow | $7.61B | $3.44B | $3.83B | $5.22B |
| Assets | $147.68B | $135.12B | $136.46B | $133.96B |
| Liabilities | $152.22B | $141.00B | $143.07B | $137.19B |
| Equity | −$4.54B | −$5.89B | −$6.61B | −$3.23B |
Technicals
Massive · Nov 12, 2026- 50-day average274.81
- 200-day average240.41
- RSI (14 days)62.2
Short interest
Massive · Oct 30, 2026- Oct 30, 202615.81M shares · 3.3 days to cover
- Oct 15, 202615.58M shares · 2.7 days to cover
- Sep 30, 202616.28M shares · 4.1 days to cover
- Sep 15, 202619.49M shares · 4.5 days to cover
Dividends
Massive · Jan 15, 2027- Ex Jan 15, 2027, paid Feb 16, 20271.8200 · 4 a year
- Ex Oct 15, 2026, paid Nov 16, 20261.7300 · 4 a year
- Ex Jul 15, 2026, paid Aug 14, 20261.7300 · 4 a year
- Ex Apr 15, 2026, paid May 15, 20261.7300 · 4 a year
- Ex Jan 16, 2026, paid Feb 17, 20261.7300 · 4 a year
- Ex Oct 15, 2025, paid Nov 14, 20251.6400 · 4 a year
- Ex Jul 15, 2025, paid Aug 15, 20251.6400 · 4 a year
- Ex Apr 15, 2025, paid May 15, 20251.6400 · 4 a year
Related companies
MassiveNews coverage
No stories about ABBVIE INC. right now.